

NCT02201316 Raw comparison:

Summary:
CHIA has 22 criteria while your personal folder has 27 criteria
Total found criteria: 21/22
Total not Found: 1/22
Total Extra: 5
This trial is INVALID



╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╕
│ CHIA Criteria                                      │ Matching Personal Criteria                         │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╡
│ Male and females aged between 18 and 65 years of   │ Male and females aged between 18 and 65 years of   │
│ age inclusive at the time of signing the informed  │ age inclusive at the time of signing the informed  │
│ consent                                            │ consent                                            │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Body weight >= 50 kilogram (kg) and body mass      │ Body weight \>= 50 kilogram (kg) and body mass     │
│ index within the range 19 - 24 9 kg/m^2            │ index within the range 19 - 24 9 kg/m\^2           │
│ (inclusive)                                        │ (inclusive)                                        │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ A female subject is eligible to participate if she │ A female subject is eligible to participate if she │
│ is of Non-childbearing potential defined as pre-   │ is of Non-childbearing potential defined as pre-   │
│ menopausal females with a documented tubal         │ menopausal females with a documented tubal         │
│ ligation or hysterectomy for this definition       │ ligation or hysterectomy for this definition       │
│ "documented" refers to the outcome of the          │ "documented" refers to the outcome of the          │
│ investigator's/designee's review of the subject's  │ investigator's/designee's review of the subject's  │
│ medical history for study eligibility as obtained  │ medical history for study eligibility as obtained  │
│ via a verbal interview with the subject or from    │ via a verbal interview with the subject or from    │
│ the subject's medical records or postmenopausal    │ the subject's medical records or postmenopausal    │
│ defined as 12 months of spontaneous amenorrhea [in │ defined as 12 months of spontaneous amenorrhea     │
│ questionable cases a blood sample with             │ \[in questionable cases a blood sample with        │
│ simultaneous follicle stimulating hormone (FSH) >  │ simultaneous follicle stimulating hormone (FSH) \> │
│ 40 milli-international units per milliliter        │ 40 milli-international units per milliliter        │
│ (MlU/mL) and estradiol < 40 picograms per          │ (MlU/mL) and estradiol \< 40 picograms per         │
│ mililiter (pg/mL) [<147 picomole per liter] is     │ mililiter (pg/mL) \[\<147 picomole per liter\] is  │
│ confirmatory] Females on hormone replacement       │ confirmatory\] Females on hormone replacement      │
│ therapy (HRT) and whose menopausal status is in    │ therapy (HRT) and whose menopausal status is in    │
│ doubt will be required to use one of the           │ doubt will be required to use one of the           │
│ contraception methods if they wish to continue     │ contraception methods if they wish to continue     │
│ their HRT during the study Otherwise they must     │ their HRT during the study Otherwise they must     │
│ discontinue HRT to allow confirmation of post-     │ discontinue HRT to allow confirmation of post-     │
│ menopausal status prior to study enrollment For    │ menopausal status prior to study enrollment For    │
│ most forms of HRT at least 2-4 weeks will elapse   │ most forms of HRT at least 2-4 weeks will elapse   │
│ between the cessation of therapy and the blood     │ between the cessation of therapy and the blood     │
│ draw this interval depends on the type and dosage  │ draw this interval depends on the type and dosage  │
│ of HRT Following confirmation of their post-       │ of HRT Following confirmation of their post-       │
│ menopausal status they can resume use of HRT       │ menopausal status they can resume use of HRT       │
│ during the study without use of a contraceptive    │ during the study without use of a contraceptive    │
│ method Child-bearing potential with negative       │ method Child-bearing potential with negative       │
│ pregnancy test as determined by serum human        │ pregnancy test as determined by serum human        │
│ chorionic gonadotrophin (hCG) test at screening or │ chorionic gonadotrophin (hCG) test at screening or │
│ prior to dosing AND Agrees to use one of the       │ prior to dosing AND Agrees to use one of the       │
│ contraception methods listed in protocol for an    │ contraception methods listed in protocol for an    │
│ appropriate period of time (as determined by the   │ appropriate period of time (as determined by the   │
│ product label or investigator) prior to the start  │ product label or investigator) prior to the start  │
│ of dosing to sufficiently minimize the risk of     │ of dosing to sufficiently minimize the risk of     │
│ pregnancy at that point Female subjects must agree │ pregnancy at that point Female subjects must agree │
│ to use contraception until the follow-up contact   │ to use contraception until the follow-up contact   │
│ visit OR has only same-sex partners when this is   │ visit OR has only same-sex partners when this is   │
│ her preferred and usual lifestyle                  │ her preferred and usual lifestyle                  │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Male subjects with female partners of child-       │ Male subjects with female partners of child-       │
│ bearing potential must agree to use one of the     │ bearing potential must agree to use one of the     │
│ contraception methods listed in Protocol This      │ contraception methods listed in Protocol This      │
│ criterion must be followed from the time of the    │ criterion must be followed from the time of the    │
│ first dose of study medication until the follow-up │ first dose of study medication until the follow-up │
│ contact visit                                      │ contact visit                                      │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Capable of giving written informed consent which   │ Capable of giving written informed consent which   │
│ includes compliance with the requirements and      │ includes compliance with the requirements and      │
│ restrictions listed in the consent form            │ restrictions listed in the consent form            │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Alanine aminotransferase alkaline phosphatase and  │ Alanine aminotransferase alkaline phosphatase and  │
│ bilirubin <=1 5x upper limit of normal (ULN)       │ bilirubin \<=1 5x upper limit of normal (ULN)      │
│ (isolated bilirubin >1 5xULN is acceptable if      │ (isolated bilirubin \>1 5xULN is acceptable if     │
│ bilirubin is fractionated and direct bilirubin     │ bilirubin is fractionated and direct bilirubin     │
│ <35%)                                              │ \<35%)                                             │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Based on single or averaged corrected QT interval  │ Based on single or averaged corrected QT interval  │
│ (QTc) values of triplicate electrocardiograms      │ (QTc) values of triplicate electrocardiograms      │
│ obtained over a brief recording period QTcF < 450  │ obtained over a brief recording period QTcF \< 450 │
│ msec                                               │ msec                                               │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Current or chronic history of liver disease or     │ Current or chronic history of liver disease or     │
│ known hepatic or biliary abnormalities (with the   │ known hepatic or biliary abnormalities (with the   │
│ exception of Gilbert's syndrome or asymptomatic    │ exception of Gilbert's syndrome or asymptomatic    │
│ gallstones)                                        │ gallstones)                                        │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ History of regular alcohol consumption within 6    │ History of regular alcohol consumption within 6    │
│ months of the study defined as An average weekly   │ months of the study defined as An average weekly   │
│ intake of >21 units for males or >14 units for     │ intake of \>21 units for males or \>14 units for   │
│ females One unit is equivalent to 8 gram of        │ females One unit is equivalent to 8 gram of        │
│ alcohol a half-pint (approximately 240 milliliter  │ alcohol a half-pint (approximately 240 milliliter  │
│ [mL]) of beer 1 glass (100 mL) of wine or 1 (25    │ \[mL\]) of beer 1 glass (100 mL) of wine or 1 (25  │
│ mL) measure of spirits                             │ mL) measure of spirits                             │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ History of sensitivity to heparin or heparin-      │ History of sensitivity to heparin or heparin-      │
│ induced thrombocytopenia                           │ induced thrombocytopenia                           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ History of sensitivity to any of the study         │ History of sensitivity to any of the study         │
│ medications or components thereof or a history of  │ medications or components thereof or a history of  │
│ drug or other allergy that in the opinion of the   │ drug or other allergy that in the opinion of the   │
│ investigator or GSK Medical Monitor                │ investigator or GSK Medical Monitor                │
│ contraindicates their participation                │ contraindicates their participation                │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Gastrointestinal disease or with gastrointestinal  │ Gastrointestinal disease or with gastrointestinal  │
│ surgical history which can affect the absorption   │ surgical history which can affect the absorption   │
│ of the investigational product                     │ of the investigational product                     │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ A positive pre-study Hepatitis B surface antigen   │ A positive pre-study Hepatitis B surface antigen   │
│ or positive Hepatitis C antibody result within 3   │ or positive Hepatitis C antibody result within 3   │
│ months of screening                                │ months of screening                                │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Urinary cotinine levels indicative of smoking or   │ Urinary cotinine levels indicative of smoking or   │
│ history or regular use of tobacco- or nicotine-    │ history or regular use of tobacco- or nicotine-    │
│ containing products within 6 months prior to       │ containing products within 6 months prior to       │
│ screening                                          │ screening                                          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ A positive pre-study drug/alcohol screen           │ A positive pre-study drug/alcohol screen           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ A positive test for Human Immunodeficiency Virus   │ A positive test for Human Immunodeficiency Virus   │
│ (HIV) antibody                                     │ (HIV) antibody                                     │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Pregnant females as determined by positive serum   │ Pregnant females as determined by positive serum   │
│ hCG test at screening or prior to dosing           │ hCG test at screening or prior to dosing           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Where participation in the study would result in   │ Where participation in the study would result in   │
│ donation of blood or blood products in excess of   │ donation of blood or blood products in excess of   │
│ 500 mL within a 90 day period                      │ 500 mL within a 90 day period                      │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Lactating females                                  │ Lactating females                                  │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ The subject has participated in a clinical trial   │ The subject has participated in a clinical trial   │
│ and has received an investigational product within │ and has received an investigational product within │
│ the following time period prior to the first       │ the following time period prior to the first       │
│ dosing day in the current study 90 days 5 half-    │ dosing day in the current study 90 days 5 half-    │
│ lives or twice the duration of the biological      │ lives or twice the duration of the biological      │
│ effect of the investigational product (whichever   │ effect of the investigational product (whichever   │
│ is longer)                                         │ is longer)                                         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Exposure to more than four new chemical entities   │ Exposure to more than four new chemical entities   │
│ within 12 months prior to the first dosing day     │ within 12 months prior to the first dosing day     │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╛



╒══════════════════════════════════════════════════════════════════════════════════════════════════════╕
│ CHIA Criteria Not Found in Personal                                                                  │
╞══════════════════════════════════════════════════════════════════════════════════════════════════════╡
│ Healthy as determined by a responsible and experienced physician based on a medical evaluation       │
│ including medical history physical examination laboratory tests and cardiac monitoring A subject     │
│ with a clinical abnormality or laboratory parameter(s) which is/are not specifically listed in the   │
│ inclusion or exclusion criteria outside the reference range for the population being studied may be  │
│ included only if the Investigator in consultation with the GSK Medical Monitor if required agree and │
│ document that the finding is unlikely to introduce additional risk factors and will not interfere    │
│ with the study procedures                                                                            │
╘══════════════════════════════════════════════════════════════════════════════════════════════════════╛



╒════════════════════════════════════════════════════════════════════════════════════════════════════╕
│ Extra Personal Criteria                                                                            │
╞════════════════════════════════════════════════════════════════════════════════════════════════════╡
│ Exclusion Criteria                                                                                 │
├────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Healthy as determined by a responsible and experienced physician based on a medical evaluation     │
│ including medical history physical examination laboratory tests and cardiac monitoring A subject   │
│ with a clinical abnormality or laboratory parameter(s) which is/are not specifically listed in the │
│ inclusion or                                                                                       │
├────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ outside the reference range for the population being studied may be included only if the           │
│ Investigator in consultation with the GSK Medical Monitor if required agree and document that the  │
│ finding is unlikely to introduce additional risk factors and will not interfere with the study     │
│ procedures                                                                                         │
├────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Must have maximum age of 65 Years                                                                  │
├────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Must have minimum age of 18 Years                                                                  │
╘════════════════════════════════════════════════════════════════════════════════════════════════════╛